Search Results
Your search for Armando E. Giuliano, MD matches 12 pages
Showing 1 - 12Using Neoadjuvant Therapy to Reduce Early Recurrences, Increase Survival in Patients With Pancreatic Cancer
USE OF THE FOLFIRINOX regimen (fluorouracil, leucovorin, irinotecan, and oxaliplatin) was associated with a 4.9-month improvement in overall survival compared to gemcitabine/ nab-paclitaxel (Abraxane) in the neoadjuvant treatment of resectable and borderline-resectable pancreatic head...
Surgery After Checkpoint Blockade for Selected Patients With Metastatic Melanoma
“In the era of improved systemic therapy, checkpoint blockade for metastatic melanoma and the ability to surgically resect all disease after treatment are associated with survival of 75%, better than what has been previously reported,” Danielle M. Bello, MD, said in summarizing study results during ...
10-Year Survival With vs Without Axillary Dissection in Invasive Breast Cancer With Sentinel-Node Metastasis
As reported in JAMA by Giuliano et al, 10-year overall survival in the ACOSOG Z0011 (Alliance) trial with sentinel lymph node dissection (SLND) alone was noninferior to that with axillary lymph node dissection (ALND) in women with clinical T1 or T2 invasive breast cancer, no palpable axillary...
ASCO Makes No Changes to 2014 Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology by Gary H. Lyman, MD, of Fred Hutchinson Cancer Research Center, and colleagues, an ASCO clinical practice guideline update panel made no changes to the 2014 recommendations for sentinel lymph node biopsy in women with early-stage breast cancer. The...
Is Observation Without Surgery a Viable Strategy for Managing Ductal Carcinoma in Situ?
In a spirited debate, abounding with citations of clinical trials and other evidence, but not without humor and mutual respect, E. Shelley Hwang, MD, MPH, and Armando E. Giuliano, MD, reviewed the data and their clinical experience managing ductal carcinoma in situ and reached opposite...
Results of Two Practice-Changing Breast Cancer Trials Upheld
Results of two pivotal breast cancer trials reported at the 2016 ASCO Annual Meeting confirmed the practice-changing findings that resulted from earlier findings. PALOMA-2 The phase III PALOMA-2 trial confirmed results from the smaller, open-label phase II PALOMA-1 trial that led to the U.S. Food...
Expert Point of View: No Value for Axillary Dissection in Patients with Breast Cancer and Occult Nodal Metastases
Two breast cancer studies presented at the 2011 Breast Cancer Symposium—NSABP B‑32 and ACOSOG Z11—suggest that aggressive approaches to surgically remove occult metastases are not necessary. Armando E. Giuliano, MD, of Cedars-Sinai Medical Center, Los Angeles, and principal investigator of ACOSOG...
No Value for Axillary Dissection in Patients with Breast Cancer and Occult Nodal Metastases
In a subanalysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 study, nearly 16% of clinically node-negative patients were found to have occult metastases upon more detailed assessment of the sentinel lymph nodes. While a slight difference in outcomes was found among this...
ASCO Guideline Update Extends Sentinel Node Biopsy Indications in Breast Cancer
The American Society of Clinical Oncology (ASCO) published its first guideline for sentinel lymph node biopsy in 2005.1 Since that time, many new randomized and cohort studies have been published investigating the indications and outcomes of the procedure. The updated 2014 guideline, recently...
ASCO Clinical Practice Guideline Update: Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer
ASCO recently convened an update committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy to develop evidence-based recommendations that update the ASCO 2005 clinical practice guideline on use of sentinel node biopsy in...
Nodal Irradiation in Node-Positive Breast Cancer: It Is Not Time to Change Practice
Management of the regional nodes in breast cancer has evolved from the era of the extended radical mastectomy to exclusion of axillary dissection in appropriately selected patients. Throughout this evolution, studies of nodal irradiation have been shown to improve locoregional control, usually...
No Increased Risk of Local Recurrence After Breast-Conserving Surgery in Triple-Negative Breast Cancer in Single-Center Study
Triple-negative breast cancer may be considered a relative contraindication to breast-conserving surgery. In a study reported in JAMA Surgery, Gangi et al from Cedars-Sinai Medical Center in Los Angeles assessed outcomes in a large cohort of women undergoing breast-conserving surgery at their...
